Is there new hope for therapeutic matrix metalloproteinase inhibition?

Nature Reviews Drug Discovery

Volumn 13, Issue 12, 2014, Pages 904-927

  Vandenbroucke, Roosmarijn E ^a,b   Libert, Claude ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; 2 [[(4 PHENOXYPHENYL)SULFONYL]METHYL]THIIRANE; 5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; AE 941; ALPHA 2 MACROGLOBULIN; BATIMASTAT; BB 1101; CIPEMASTAT; COLLAGENASE 3; DOXYCYCLINE; FN 439; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; ILOMASTAT; INCYCLINIDE; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; NEUTROPHIL COLLAGENASE; PROTEINASE ACTIVATED RECEPTOR 1; REBIMASTAT; RO 28 2653; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; AUTACOID;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN ISCHEMIA; BREAST CANCER; BREAST METASTASIS; CAROTID ARTERY OBSTRUCTION; COLITIS; COLLAGENOUS COLITIS; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DIVERTICULITIS; DRUG BINDING SITE; DRUG STRUCTURE; ENDOTOXEMIA; ESCHERICHIA COLI INFECTION; EXPERIMENTAL COLITIS; HEMANGIOMA; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; KIDNEY ISCHEMIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MIDDLE CEREBRAL ARTERY OCCLUSION; MUSCULOSKELETAL PAIN; NECROTIZING ENTEROCOLITIS; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OSTEOARTHRITIS; OVARY CANCER; PERIODONTAL DISEASE; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SUBARACHNOID HEMORRHAGE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRAUMATIC BRAIN INJURY; ULCERATIVE COLITIS; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; INFLAMMATION; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84927177593     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4390     Document Type: Review

References (303)

1. Gialeli, C., Theocharis, A. D. & Karamanos, N. K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278, 16-27 (2011).
2. Davies, B., Brown, P. D., East, N., Crimmin, M. J. & Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53, 2087-2091 (1993).
3. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002).
4. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-174 (2002).
5. Fisher, J. F. & Mobashery, S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 25, 115-136 (2006).
6. Overall, C. M. & Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94, 941-946 (2006).
7. Overall, C. M. & Kleifeld, O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Rev. Cancer 6, 227-239 (2006).
8. Pirard, B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov. Today 12, 640-646 (2007).
9. Rao, B. G. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Design 11, 295-322 (2005).
10. Pavlaki, M. & Zucker, S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 22, 177-203 (2003).
11. Overall, C. M. & Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer 2, 657-672 (2002).
12. Iyer, R. P., Patterson, N. L., Fields, G. B. & Lindsey, M. L. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am. J. Physiol. Heart Circ. Physiol. 303, H919-H930 (2012).
13. Hadler-Olsen, E., Winberg, J. O. & Uhlin-Hansen, L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 34, 2041-2051 (2013).
14. Decock, J., Thirkettle, S., Wagstaff, L. & Edwards, D. R. Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med. 15, 1254-1265 (2011).
15. Lopez-Otin, C., Palavalli, L. H. & Samuels, Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 8, 3657-3662 (2009).
16. Vanlaere, I. & Libert, C. Matrix metalloproteinases as drug targets in infections caused by Gram-negative bacteria and in septic shock. Clin. Microbiol. Rev. 22, 224-239 (2009).
17. Drummond, A. H. et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. Sci. 878, 228-235 (1999).
18. Skiles, J. W., Gonnella, N. C. & Jeng, A. Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem. 11, 2911-2977 (2004).
19. Edwards, D. R., Handsley, M. M. & Pennington, C. J. The ADAM metalloproteinases. Mol. Aspects Med. 29, 258-289 (2008).
20. Tan Ide, A., Ricciardelli, C. & Russell, D. L. The metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways. Int. J. Cancer 133, 2263-2276 (2013).
21. Khokha, R., Murthy, A. & Weiss, A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nature Rev. Immunol. 13, 649-665 (2013).
22. Gross, J. & Lapiere, C. M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl Acad. Sci. USA 48, 1014-1022 (1962).
23. Sterchi, E. E. Special issue: metzincin metallo proteinases. Mol. Aspects Med. 29, 255-257 (2008).
24. Ra, H. J. & Parks, W. C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596 (2007).
25. Fanjul-Fernandez, M., Folgueras, A. R., Cabrera, S. & Lopez-Otin, C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 1803, 3-19 (2010).
26. Butler, G. S. & Overall, C. M. Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nature Rev. Drug Discov. 8, 935-948 (2009).
27. Sorokin, L. The impact of the extracellular matrix on inflammation. Nature Rev. Immunol. 10, 712-723 (2010).
28. Cauwe, B., Van den Steen, P. E. & Opdenakker, G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42, 113-185 (2007).
29. Page-McCaw, A., Ewald, A. J. & Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nature Rev. Mol. Cell Biol. 8, 221-233 (2007).
30. Loffek, S., Schilling, O. & Franzke, C. W. Series "matrix metalloproteinases in lung health and disease": biological role of matrix metalloproteinases: a critical balance. Eur. Respir. J. 38, 191-208 (2011).
31. Mannello, F. & Gazzanelli, G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 6, 479-482 (2001).
32. Troeberg, L. & Nagase, H. Analysis of TIMP expression and activity. Methods Mol. Med. 135, 251-267 (2007).
33. Nagase, H., Visse, R. & Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Res. 69, 562-573 (2006).
34. Murphy, G. Tissue inhibitors of metalloproteinases. Genome Biol. 12, 233 (2011).
35. Leco, K. J. et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J. Clin. Invest. 108, 817-829 (2001).
36. Fata, J. E. et al. Accelerated apoptosis in the Timp-3-deficient mammary gland. J. Clin. Invest. 108, 831-841 (2001).
37. -/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nature Genet. 36, 969-977 (2004).
38. Whittaker, M., Floyd, C. D., Brown, P. & Gearing, A. J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99, 2735-2776 (1999).
39. Verma, R. P. Hydroxamic acids as matrix metallo-proteinase inhibitors. EXS 103, 137-176 (2012).
40. Macaulay, V. M. et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 5, 513-520 (1999).
41. Acharya, M. R., Venitz, J., Figg, W. D. & Sparreboom, A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat. 7, 195-208 (2004).
42. Eccles, S. A. et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 56, 2815-2822 (1996).
43. Sledge, G. W. et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl Cancer Inst. 87, 1546-1550 (1995).
44. Low, J. A., Johnson, M. D., Bone, E. A. & Dickson, R. B. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res. 2, 1207-1214 (1996).
45. Watson, S. A. et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 55, 3629-3633 (1995).
46. Chirivi, R. G. et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer 58, 460-464 (1994).
47. Taraboletti, G. et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl Cancer Inst. 87, 293-298 (1995).
48. Mannello, F., Tonti, G. & Papa, S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets 5, 285-298 (2005).
49. Vihinen, P., Ala-aho, R. & Kahari, V. M. Matrix metalloproteinases as therapeutic targets in cancer. Curr. Cancer Drug Targets 5, 203-220 (2005).
50. Sparano, J. A. et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 22, 4683-4690 (2004).
51. Goffin, J. R. et al. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 11, 3417-3424 (2005).
52. Fingleton, B. MMPs as therapeutic targets-still a viable option? Semin. Cell Dev. Biol. 19, 61-68 (2008).
53. Fingleton, B. Matrix metalloproteinases: roles in cancer and metastasis. Front. Biosci. 11, 479-491 (2006).
54. Kruger, A., Kates, R. E. & Edwards, D. R. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim. Biophys. Acta 1803, 95-102 (2010).
55. Eatock, M. et al. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother. Pharmacol. 55, 39-46 (2005).
56. Hoekstra, R., Eskens, F. A. & Verweij, J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncol. 6, 415-427 (2001).
57. Close, D. R. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis. 60, iii62-iii67 (2001).
58. Li, J., et al. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 15, 4961-4966 (2005).
59. de Melo, E. B. A QSAR study of matrix metalloproteinases type 2 (MMP-2) inhibitors with cinnamoyl pyrrolidine derivatives. Scientia pharmaceutica 80, 265-281 (2012).
60. Jacobsen, J. A., Major Jourden, J. L., Miller, M. T. & Cohen, S. M. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim. Biophys. Acta 1803, 72-94 (2010).
61. Naglich, J. G. et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 61, 8480-8485 (2001).
62. Miller, K. D. et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin. Cancer Res. 10, 1971-1975 (2004).
63. Leighl, N. B. et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J. Clin. Oncol. 23, 2831-2839 (2005).
64. Lutz, J. et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 79, 655-661 (2005).
65. Lee, M. et al. Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org. Lett. 7, 4463-4465 (2005).
66. Ikejiri, M. et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem. 280, 33992-34002 (2005).
67. Ikejiri, M. et al. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J. Org. Chem. 70, 5709-5712 (2005).
68. Grams, F. et al. Pyrimidine-2, 4, 6-triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol. Chem. 382, 1277-1285 (2001).
69. Lein, M. et al. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 21, 2089-2096 (2002).
70. Abramjuk, C. et al. Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats. Anticancer Drugs 16, 855-861 (2005).
71. Kilian, M. et al. Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins Leukot. Essent. Fatty Acids 75, 429-434 (2006).
72. Maquoi, E. et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2, 4, 6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin. Cancer Res. 10, 4038-4047 (2004).
73. De Savi, C. et al. Hydantoin based inhibitors of MMP13-discovery of AZD6605. Bioorg. Med. Chem. Lett. 23, 4705-4712 (2013).
74. Hu, Y. et al. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. 13, 6629-6644 (2005).
75. Li, J. et al. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 15, 4961-4966 (2005).
76. Wu, J. et al. Identification of potent and selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 15, 4105-4109 (2005).
77. Dive, V. et al. Phosphinic peptides as zinc metalloproteinase inhibitors. Cell. Mol. Life Sci. 61, 2010-2019 (2004).
78. Reiter, L. A. et al. Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg. Med. Chem. Lett. 13, 2331-2336 (2003).
79. Dive, V. et al. Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases. Int. J. Cancer 11 3, 775-781 (2005).
80. Sorsa, T. et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann. Med. 38, 306-321 (2006).
81. Rudek, M. A. et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol. 19, 584-592 (2001).
82. Schechter, I. & Berger, A. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem. Biophys. Res. Commun. 32, 898-902 (1968).
83. Aureli, L. et al. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Curr. Med. Chem. 15, 2192-2222 (2008).
84. Park, H. I. et al. The intermediate S1? pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J. Biol. Chem. 278, 51646-51653 (2003).
85. Gupta, S. P. & Patil, V. M. Specificity of binding with matrix metalloproteinases. EXS 103, 35-56 (2012).
86. Gupta, S. P. Matrix metalloproteinase inhibitors: specificity of binding and structure-activity relationships. EXS 103, v-vi (2012).
87. Gege, C. et al. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J. Med. Chem. 55, 709-716 (2012).
88. Jungel, A. et al. Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann. Rheum. Dis. 69, 898-902 (2010).
89. Schnute, M. E. et al. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. Lett. 20, 576-580 (2010).
90. Fabre, B. et al. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily. Chembiochem. 15, 399-412 (2014).
91. Roth, J. et al. Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg. Med. Chem. Lett. 21, 7180-7184 (2011).
92. Udi, Y. et al. Unraveling hidden regulatory sites in structurally homologous metalloproteases. J. Mol. Biol. 425, 2330-2346 (2013).
93. Ndinguri, M. W., Bhowmick, M., Tokmina-Roszyk, D., Robichaud, T. K. & Fields, G. B. Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities. Molecules 17, 14230-14248 (2012).
94. Koivunen, E. et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotech. 17, 768-774 (1999).
95. Suojanen, J., Salo, T., Koivunen, E., Sorsa, T. & Pirila, E. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol. Ther. 8, 2362-2370 (2009).
96. Devy, L. & Dransfield, D. T. New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem. Res. Int. 2011, 191670 (2011).
97. Hoet, R. M. et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nature Biotech. 23, 344-348 (2005).
98. Devy, L. et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69, 1517-1526 (2009).
99. Ingvarsen, S. et al. Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. J. Biol. Chem. 288, 10195-10204 (2013).
100. Kaimal, R. et al. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res. 73, 2457-2467 (2013).
101. Basu, B. et al. Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. Int. J. Biochem. Cell Biol. 44, 393-403 (2012).
102. Hu, J., Van den Steen, P. E., Houde, M., Ilenchuk, T. T. & Opdenakker, G. Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochem. Pharmacol. 67, 1001-1009 (2004).
103. Martens, E. et al. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim. Biophys. Acta 1770, 178-186 (2007).
104. Shiryaev, S. A. et al. A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP. Oncogenesis 2, e80 (2013).
105. Sela-Passwell, N. et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nature Med. 18, 143-147 (2012).
106. Naito, S. et al. Development of a neutralizing antibody specific for the active form of matrix metallo-proteinase-13. Biochemistry 51, 8877-8884 (2012).
107. Bu, Z. et al. SZ-117, a monoclonal antibody against matrix metalloproteinase-2 inhibits tumor cell-mediated angiogenesis. Hybridoma 31, 63-67 (2012).
108. Tchetverikov, I. et al. Active MMPs captured by alpha 2 macroglobulin as a marker of disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol 21, 711-718 (2003).
109. Etique, N., Verzeaux, L., Dedieu, S. & Emonard, H. LRP-1: a checkpoint for the extracellular matrix proteolysis. BioMed Res. Int. 2013, 152163 (2013).
110. Birkenmeier, G. et al. Polymyxin B-conjugated α2-macroglobulin as an adjunctive therapy to sepsis: modes of action and impact on lethality. J. Pharmacol. Exp. Ther. 318, 762-771 (2006).
111. Webb, D. J. & Gonias, S. L. A modified human alpha 2-macroglobulin derivative that binds tumor necrosis factor-alpha and interleukin-1 beta with high affinity in vitro and reverses lipopolysaccharide toxicity in vivo in mice. Lab. Invest. 78, 939-948 (1998).
112. Amour, A. et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473, 275-279 (2000).
113. Smookler, D. S. et al. Tissue inhibitor of metallo-proteinase 3 regulates TNF-dependent systemic inflammation. J. Immunol. 176, 721-725 (2006).
114. Vanhoutte, D. & Heymans, S. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'. J. Mol. Cell Cardiol. 48, 445-453 (2010).
115. Moore, C. S. & Crocker, S. J. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am. J. Pathol. 180, 12-16 (2012).
116. Stetler-Stevenson, W. G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 1, re6 (2008).
117. Seo, D. W. et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114, 171-180 (2003).
118. Stetler-Stevenson, W. G. & Seo, D. W. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol. Med. 11, 97-103 (2005).
119. Nieuwesteeg, M. A., Walsh, L. A., Fox, M. A. & Damjanovski, S. Domain specific overexpression of TIMP-2 and TIMP-3 reveals MMP-independent functions of TIMPs during Xenopus laevis development. Biochem. Cell Biol. 90, 585-595 (2012).
120. Butler, G. S. et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J. Biol. Chem. 273, 871-880 (1998).
121. Hu, J., Van den Steen, P. E., Sang, Q. X. & Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Rev. Drug Discov. 6, 480-498 (2007).
122. Qiu, Z., Hu, J., Van den Steen, P. E. & Opdenakker, G. Targeting matrix metalloproteinases in acute inflammatory shock syndromes. Comb. Chem. High Throughput Screen. 15, 555-570 (2012).
123. Vandenbroucke, R. E., Dejonckheere, E. & Libert, C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur. Respir. J. 38, 1200-1214 (2011).
124. Dejonckheere, E., Vandenbroucke, R. E. & Libert, C. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov. Today 16, 762-778 (2011).
125. Newby, A. C. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul. Pharmacol. 56, 232-244 (2012).
126. Yabluchanskiy, A., Ma, Y., Iyer, R. P., Hall, M. E. & Lindsey, M. L. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology 28, 391-403 (2013).
127. Halade, G. V., Jin, Y. F. & Lindsey, M. L. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol. Ther. 139, 32-40 (2013).
128. Nissinen, L. & Kahari, V. M. Matrix metalloproteinases in inflammation. Biochim. Biophys. Acta 1840, 2571-2580 (2014).
129. Angus, D. C. & van der Poll, T. Severe sepsis and septic shock. N. Engl. J. Med. 369, 2063 (2013).
130. Marti-Carvajal, A. J., Sola, I., Gluud, C., Lathyris, D. & Cardona, A. F. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst. Rev. 12, CD004388 (2012).
131. Deutschman, C. S. Steroid responses in sepsis: some novel thinking that may provide new insight. Crit. Care 17, 147 (2013).
132. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507-3512 (2013).
133. Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 19, 198-208 (2011).
134. Okamoto, T. et al. Activation of human matrix metalloproteinases by various bacterial proteinases. J. Biol. Chem. 272, 6059-6066 (1997).
135. Elkington, P. T., Green, J. A. & Friedland, J. S. Analysis of matrix metalloproteinase secretion by macrophages. Methods Mol. Biol. 531, 253-265 (2009).
136. Lalu, M. M., Cena, J., Chowdhury, R., Lam, A. & Schulz, R. Matrix metalloproteinases contribute to endotoxin and interleukin-1β induced vascular dysfunction. Br. J. Pharmacol. 149, 31-42 (2006).
137. Dubois, B. et al. Gelatinase B deficiency protects against endotoxin shock. Eur. J. Immunol. 32, 2163-2171 (2002).
138. Barichello, T. et al. Inhibition of matrix metalloproteinases-2 and-9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats. Exp. Biol. Med. 239, 225-231 (2014).
139. Pagenstecher, A., Stalder, A. K., Kincaid, C. L., Volk, B. & Campbell, I. L. Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am. J. Pathol. 157, 197-210 (2000).
140. Rahman, M. et al. Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis. Inflamm. Res. 61, 571-579 (2012).
141. Chen, J. et al. Biodistribution of radiolabeled [(3)H] CMT-3 in rats. Curr. Med. Chem. 8, 253-256 (2001).
142. Liu, Y. et al. The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). Curr. Med. Chem. 8, 243-252 (2001).
143. Steinberg, J. et al. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J. Surg. Res. 111, 185-195 (2003).
144. Vandooren, J., Van den Steen, P. E. & Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit. Rev. Biochem. Mol. Biol. 48, 222-272 (2013).
145. Muhl, D. et al. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J. Crit. Care 26, 550-555 (2011).
146. Maitra, S. R., Jacob, A., Zhou, M. & Wang, P. Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis. Int. J. Clin. Exp. Med. 3, 180-185 (2010).
147. Hu, J., Van den Steen, P. E., Dillen, C. & Opdenakker, G. Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem. Pharmacol. 70, 535-544 (2005).
148. Renckens, R. et al. Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J. Immunol. 176, 3735-3741 (2006).
149. Dal-Pizzol, F. et al. Matrix metalloproteinase-2 and metalloproteinase-9 activities are associated with blood-brain barrier dysfunction in an animal model of severe sepsis. Mol. Neurobiol. 48, 62-70 (2013).
150. Tressel, S. L. et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol. Med. 3, 370-384 (2011).
151. Schouten, M., Wiersinga, W. J., Levi, M. & van der Poll, T. Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol. 83, 536-545 (2008).
152. Vandenbroucke, R. E., Dejager, L. & Libert, C. The first MMP in sepsis. EMBO Mol. Med. 3, 367-369 (2011).
153. Fanjul-Fernandez, M. et al. Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J. Biol. Chem. 288, 14647-14656 (2013).
154. Van Lint, P. & Libert, C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 17, 217-223 (2006).
155. Dejonckheere, E., Vandenbroucke, R. E. & Libert, C. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev. 22, 73-81 (2011).
156. Tester, A. M. et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS ONE 2, e312 (2007).
157. Lauhio, A. et al. Serum MMP-8,-9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol. Res. 64, 590-594 (2011).
158. Solan, P. D. et al. A novel role for matrix metalloproteinase-8 in sepsis. Crit. Care Med. 40, 379-387 (2012).
159. Punyadeera, C. et al. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J. Emerg. Trauma Shock 3, 26-35 (2010).
160. Hoffmann, U., Brueckmann, M. & Borggrefe, M. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis? Crit. Care 13, 1006 (2009).
161. Vandenbroucke, R. E. et al. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. J. Neurosci. 32, 9805-9816 (2012).
162. Gonzalez-Lopez, A. et al. MMP-8 deficiency increases TLR/RAGE ligands S100A8 and S100A9 and exacerbates lung inflammation during endotoxemia. PLoS ONE 7, e39940 (2012).
163. Singh, A. et al. Collagenase-3 (MMP-13) deficiency protects C57BL/6 mice from antibody-induced arthritis. Arthritis Res. Ther. 15, R222 (2013).
164. Toriseva, M. et al. MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability. PLoS ONE 7, e42596 (2012).
165. Li, N. G., Tang, Y. P. & Duan, J. A. New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158). Expert Opin. Ther. Pat. 23, 669-675 (2013).
166. Muddasani, P., Norman, J. C., Ellman, M., van Wijnen, A. J. & Im, H. J. Basic fibroblast growth factor activates the MAPK and NFκB pathways that converge on Elk-1 to control production of matrix metallo proteinase-13 by human adult articular chondrocytes. J. Biol. Chem. 282, 31409-31421 (2007).
167. Ahmad, R., Sylvester, J. & Zafarullah, M. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation. Cell Signal. 19, 2549-2557 (2007).
168. Uhlenhaut, N. H. et al. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol. Cell 49, 158-171 (2013).
169. Vandenbroucke, R. E. et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol. Med. 5, 932-948 (2013).
170. Carrico, C. J., Meakins, J. L., Marshall, J. C., Fry, D. & Maier, R. V. Multiple-organ-failure syndrome. Arch. Surg. 121, 196-208 (1986).
171. Deitch, E. A. & Berg, R. Bacterial translocation from the gut: a mechanism of infection. J. Burn Care Rehabil. 8, 475-482 (1987).
172. Gearing, A. J. et al. Matrix metalloproteinases and processing of pro-TNF-α. J. Leukoc. Biol. 57, 774-777 (1995).
173. Chandler, S., Cossins, J., Lury, J. & Wells, G. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-α fusion protein. Biochem. Biophys. Res. Commun. 228, 421-429 (1996).
174. d'Ortho, M. P. et al. Membrane-type matrix metallo-proteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metallo-proteinases. Eur. J. Biochem. 250, 751-757 (1997).
175. Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, M. S. & Overall, C. M. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl Acad. Sci. USA 101, 6917-6922 (2004).
176. Becker-Pauly, C. & Rose-John, S. TNFα cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis. EMBO Mol. Med. 5, 902-904 (2013).
177. Marchenko, G. N. & Strongin, A. Y. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene 265, 87-93 (2001).
178. Vandenbroucke, R. E. et al. Pro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation. Mucosal Immunol. 7, 579-588 (2014).
179. Gaddnas, F. P. et al. Matrix-metalloproteinase-2,-8 and-9 in serum and skin blister fluid in patients with severe sepsis. Crit. Care 14, R49 (2010).
180. MacDonald, T. T., Monteleone, I., Fantini, M. C. & Monteleone, G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 140, 1768-1775 (2011).
181. Giuffrida, P., Biancheri, P. & Macdonald, T. T. Proteases and small intestinal barrier function in health and disease. Curr. Opin. Gastroenterol. 30, 147-153 (2014).
182. Medina, C. & Radomski, M. W. Role of matrix metalloproteinases in intestinal inflammation. J. Pharmacol. Exp. Ther. 318, 933-938 (2006).
183. Pedersen, J., Coskun, M., Soendergaard, C., Salem, M. & Nielsen, O. H. Inflammatory pathways of importance for management of inflammatory bowel disease. World J. Gastroenterol. 20, 64-77 (2014).
184. Billiet, T., Rutgeerts, P., Ferrante, M., Van Assche, G. & Vermeire, S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin. Biol. Ther. 14, 75-101 (2014).
185. Podolsky, D. K. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease. Dig. Dis. 27, 366-369 (2009).
186. Morgan, A. R. et al. Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Hum. Immunol. 72, 1117-1127 (2011).
187. Sykes, A. P. et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment. Pharmacol. Ther. 13, 1535-1542 (1999).
188. Di Sebastiano, P. et al. Beneficial effects of batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 63, 234-239 (2001).
189. Gingras, D. et al. Neovastat-a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14, 91-96 (2003).
190. Gingras, D., Batist, G. & Beliveau, R. AE-941 (neovastat): a novel multifunctional antiangiogenic compound. Expert Rev. Anticancer Ther. 1, 341-347 (2001).
191. Mao, J. W., He, X. M., Tang, H. Y. & Wang, Y. D. Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats. World J. Gastroenterol. 18, 7063-7069 (2012).
192. Huang, T. Y. et al. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol. Appl. Pharmacol. 237, 69-82 (2009).
193. Wang, Y. D. & Wang, W. Protective effect of ilomastat on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. World J. Gastroenterol. 14, 5683-5688 (2008).
194. Naito, Y. et al. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm. Res. 53, 462-468 (2004).
195. Medina, C. et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G116-G122 (2003).
196. Rath, T. et al. Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand. J. Gastroenterol. 45, 1186-1196 (2010).
197. von Lampe, B., Barthel, B., Coupland, S. E., Riecken, E. O. & Rosewicz, S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47, 63-73 (2000).
198. Lakatos, G. et al. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig. Dis. 30, 289-295 (2012).
199. Koelink, P. J. et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 63, 578-587 (2014).
200. Santana, A. et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J. Gastroenterol. 12, 6464-6472 (2006).
201. Castaneda, F. E. et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 129, 1991-2008 (2005).
202. Liu, H. et al. Constitutive expression of MMP9 in intestinal epithelium worsens murine acute colitis and is associated with increased levels of proinflammatory cytokine Kc. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G793-G803 (2013).
203. Ishida, K. et al. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J. Pharmacol. Exp. Ther. 324, 422-426 (2008).
204. Rodrigues, D. M. et al. Matrix metalloproteinase 9 contributes to gut microbe homeostasis in a model of infectious colitis. BMC Microbiol. 12, 105 (2012).
205. Garg, P. et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J. Immunol. 177, 4103-4112 (2006).
206. Garg, P. et al. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am. J. Physiol. Gastrointest Liver Physiol. 296, G175-G184 (2009).
207. Wang, Y. D., Tan, X. Y. & Zhang, K. Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis. Mediators Inflamm. 2009, 275072 (2009).
208. Stallmach, A. et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 47, 415-422 (2000).
209. Wang, Y. D. & Yan, P. Y. Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis. World J. Gastroenterol. 12, 6050-6053 (2006).
210. Wang, Y. D. & Mao, J. W. Expression of matrix metalloproteinase-1 and tumor necrosis factor-α in ulcerative colitis. World J. Gastroenterol. 13, 5926-5932 (2007).
211. Gordon, J. N. et al. Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm. Bowel Dis. 14, 195-203 (2008).
212. Meijer, M. J. et al. Increased mucosal matrix metalloproteinase-1,-2,-3 and-9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig. Liver Dis. 39, 733-739 (2007).
213. Kruidenier, L., MacDonald, T. T., Collins, J. E., Pender, S. L. & Sanderson, I. R. Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant CXCL7 from intestinal epithelial cells. Gastroenterology 130, 127-136 (2006).
214. Kobayashi, K. et al. Therapeutic implications of the specific inhibition of causative matrix metallo-proteinases in experimental colitis induced by dextran sulphate sodium. J. Pathol. 209, 376-383 (2006).
215. Koller, F. L. et al. Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia. Lab. Invest. 92, 1749-1759 (2012).
216. Hackam, D. J., Afrazi, A., Good, M. & Sodhi, C. P. Innate immune signaling in the pathogenesis of necrotizing enterocolitis. Clin. Dev. Immunol. 2013, 475415 (2013).
217. Pender, S. L. et al. Matrix metalloproteinases in necrotising enterocolitis. Pediatr. Res. 54, 160-164 (2003).
218. Bister, V. et al. Matrilysins-1 and-2 (MMP-7 and-26) and metalloelastase (MMP-12), unlike MMP-19, are up-regulated in necrotizing enterocolitis. J. Pediatr. Gastroenterol. Nutr. 40, 60-66 (2005).
219. Gunther, U. et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and-13, and TIMP-1 gene expression. Am. J. Pathol. 155, 493-503 (1999).
220. Altadill, A. et al. Comparative analysis of the expression of metalloproteases and their inhibitors in resected crohn's disease and complicated diverticular disease. Inflamm. Bowel Dis. 18, 120-130 (2012).
221. Rosemar, A., Ivarsson, M. L., Borjesson, L. & Holmdahl, L. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease. Scand. J. Gastroenterol. 42, 215-220 (2007).
222. Morancho, A., Rosell, A., Garcia-Bonilla, L. & Montaner, J. Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? Ann. NY Acad. Sci. 1207, 123-133 (2010).
223. Romi, F., Helgeland, G. & Gilhus, N. E. Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur. Neurol. 67, 121-128 (2012).
224. Seo, J. H. et al. Neurovascular matrix metalloproteinases and the blood-brain barrier. Curr. Pharm. Design 18, 3645-3648 (2012).
225. Florczak-Rzepka, M., Grond-Ginsbach, C., Montaner, J. & Steiner, T. Matrix metalloproteinases in human spontaneous intracerebral hemorrhage: an update. Cerebrovasc. Dis. 34, 249-262 (2012).
226. Yamashita, T. & Abe, K. Therapeutic approaches to vascular protection in ischemic stroke. Acta Med. Okayama 65, 219-223 (2011).
227. Mroczko, B., Groblewska, M. & Barcikowska, M. The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study. J. Alzheimers Dis. 37, 273-283 (2013).
228. Elgebaly, M. M. et al. Vascular protection in diabetic stroke: role of matrix metalloprotease-dependent vascular remodeling. J. Cereb. Blood Flow Metab. 30, 1928-1938 (2010).
229. Kurzepa, J., Kurzepa, J., Golab, P., Czerska, S. & Bielewicz, J. The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke. Int. J. Neurosci. Error! Hyperlink reference not valid. (2014).
230. Chaturvedi, M. & Kaczmarek, L. MMP-9 inhibition: a therapeutic strategy in ischemic stroke. Mol. Neurobiol. 49, 563-573 (2014).
231. Zheng, K. et al. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with moderate and severe traumatic brain injury. Neurol. India 61, 606-609 (2013).
232. Ulrich, N. H., Dehmel, T., Wittsack, H. J., Kieseier, B. C. & Seitz, R. J. Peripheral blood levels of matrix metalloproteinase-9 predict lesion volume in acute stroke. Neurol. Sci. 34, 379-382 (2013).
233. Svedin, P., Hagberg, H., Savman, K., Zhu, C. & Mallard, C. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J. Neurosci. 27, 1511-1518 (2007).
234. Wang, X. et al. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J. Neurosci. 20, 7037-7042 (2000).
235. Asahi, M. et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724-7732 (2001).
236. Gidday, J. M. et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 289, H558-568 (2005).
237. Shichi, K. et al. Involvement of matrix metalloproteinase-mediated proteolysis of neural cell adhesion molecule in the development of cerebral ischemic neuronal damage. J. Pharmacol. Exp. Ther. 338, 701-710 (2011).
238. Hu, Q. et al. Lentivirus-mediated transfer of MMP-9 shRNA provides neuroprotection following focal ischemic brain injury in rats. Brain Res. 1367, 347-359 (2011).
239. Romanic, A. M., White, R. F., Arleth, A. J., Ohlstein, E. H. & Barone, F. C. Matrix metallo proteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metallo proteinase-9 reduces infarct size. Stroke 29, 1020-1030 (1998).
240. Hu, Q. et al. Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Exp. Neurol. 216, 35-46 (2009).
241. Verslegers, M., Lemmens, K., Van Hove, I. & Moons, L. Matrix metalloproteinase-2 and-9 as promising benefactors in development, plasticity and repair of the nervous system. Progress Neurobiol. 105, 60-78 (2013).
242. Asahi, M., Sumii, T., Fini, M. E., Itohara, S. & Lo, E. H. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 12, 3003-3007 (2001).
243. Walker, E. J. & Rosenberg, G. A. TIMP-3 and MMP-3 contribute to delayed inflammation and hippocampal neuronal death following global ischemia. Exp. Neurol. 216, 122-131 (2009).
244. Hadass, O. et al. Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury. PLoS ONE 8, e76904 (2013).
245. Jiang, J. Y. et al. MMP-9 inhibitor SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat. J. Neurotrauma 31, 1225-1234 (2014).
246. Cui, J. et al. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol. Neurodegener. 7, 21 (2012).
247. Ranasinghe, H. S. et al. Inhibition of MMP-9 activity following hypoxic ischemia in the developing brain using a highly specific inhibitor. Dev. Neurosci. 34, 417-427 (2012).
248. Guo, Z. D. et al. Matrix metalloproteinase 9 inhibition reduces early brain injury in cortex after subarachnoid hemorrhage. Acta Neurochir. Suppl. 110, 81-84 (2011).
249. Burggraf, D., Trinkl, A., Dichgans, M. & Hamann, G. F. Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. Neurobiol. Dis. 25, 506-513 (2007).
250. Copin, J. C., Merlani, P., Sugawara, T., Chan, P. H. & Gasche, Y. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp. Neurol. 213, 196-201 (2008).
251. Lee, H., Park, J. W., Kim, S. P., Lo, E. H. & Lee, S. R. Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia. Neurobiol. Dis. 34, 189-198 (2009).
252. Pires, P. W. et al. Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 301, H87-H97 (2011).
253. Wang, Z., Xue, Y., Jiao, H., Liu, Y. & Wang, P. Doxycycline-mediated protective effect against focal cerebral ischemia-reperfusion injury through the modulation of tight junctions and PKCδ signaling in rats. J. Mol. Neurosci. 47, 89-100 (2012).
254. Yrjanheikki, J. et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl Acad. Sci. USA 96, 13496-13500 (1999).
255. Yrjanheikki, J., Keinanen, R., Pellikka, M., Hokfelt, T. & Koistinaho, J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl Acad. Sci. USA 95, 15769-15774 (1998).
256. Bhatt, L. K. & Addepalli, V. Potentiation of aspirin-induced cerebroprotection by minocycline: a therapeutic approach to attenuate exacerbation of transient focal cerebral ischaemia. Diab. Vasc. Dis. Res. 9, 25-34 (2012).
257. Pfefferkorn, T. & Rosenberg, G. A. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34, 2025-2030 (2003).
258. Walker, E. J. & Rosenberg, G. A. Divergent role for MMP-2 in myelin breakdown and oligodendrocyte death following transient global ischemia. J. Neurosci. Res. 88, 764-773 (2010).
259. Zhao, B. Q. et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nature Med. 12, 441-445 (2006).
260. Liu, W., Hendren, J., Qin, X. J., Shen, J. & Liu, K. J. Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J. Neurochem. 108, 811-820 (2009).
261. Rosenberg, G. A., Estrada, E. Y. & Dencoff, J. E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29, 2189-2195 (1998).
262. Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W. & Rosenberg, G. A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 27, 697-709 (2007).
263. Sood, R. R., Taheri, S., Candelario-Jalil, E., Estrada, E. Y. & Rosenberg, G. A. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J. Cereb. Blood Flow Metab. 28, 431-438 (2008).
264. Yang, Y. et al. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J. Neurochem. 11 2, 134-149 (2010).
265. Amantea, D., Corasaniti, M. T., Mercuri, N. B., Bernardi, G. & Bagetta, G. Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion. Neuroscience 152, 8-17 (2008).
266. Chen, W. et al. Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J. Neurochem. 111, 726-736 (2009).
267. Gu, Z. et al. S-nitrosylation of matrix metallo-proteinases: signaling pathway to neuronal cell death. Science 297, 1186-1190 (2002).
268. Lee, S. R. et al. Involvement of matrix metallo-proteinase in neuroblast cell migration from the subventricular zone after stroke. J. Neurosci. 26, 3491-3495 (2006).
269. Yang, Y. et al. Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery. J. Cereb. Blood Flow Metab. 33, 1104-1114 (2013).
270. Mishiro, K. et al. A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice. Neuroscience 205, 39-48 (2012).
271. Nagel, S. et al. Selective MMP-inhibition with Ro 28-2653 in acute experimental stroke-a magnetic resonance imaging efficacy study. Brain Res. 1368, 264-270 (2011).
272. Thomsen, L. B. et al. Brain delivery systems via mechanism independent of receptor-mediated endocytosis and adsorptive-mediated endocytosis. Curr. Pharm. Biotechnol. 13, 2349-2354 (2012).
273. Guo, L., Ren, J. & Jiang, X. Perspectives on brain-targeting drug delivery systems. Curr. Pharm. Biotechnol. 13, 2310-2318 (2012).
274. Tang, Y. et al. MT1-MMP-dependent control of skeletal stem cell commitment via a beta1-integrin/YAP/TAZ signaling axis. Dev. Cell 25, 402-416 (2013).
275. Dufour, A. & Overall, C. M. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol. Sci. 34, 233-242 (2013).
276. Ghosh, D. et al. Paneth cell trypsin is the processing enzyme for human defensin-5. Nature Immunol. 3, 583-590 (2002).
277. Lindsey, M. L. & Zamilpa, R. Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovascular Ther. 30, 31-41 (2012).
278. Scherer, R. L., McIntyre, J. O. & Matrisian, L. M. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev. 27, 679-690 (2008).
279. Yang, K. et al. Visualization of protease activity in vivo using an activatable photo-acoustic imaging probe based on CuS nanoparticles. Theranostics 4, 134-141 (2014).
280. Waschkau, B., Faust, A., Schafers, M. & Bremer, C. Performance of a new fluorescence-labeled MMP inhibitor to image tumor MMP activity in vivo in comparison to an MMP-activatable probe. Contrast Media Mol. Imag. 8, 1-11 (2013).
281. Matusiak, N. et al. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Curr. Pharm. Design 19, 4647-4672 (2013).
282. Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Design 13, 333-346 (2007).
283. Roy, R., Yang, J. & Moses, M. A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27, 5287-5297 (2009).
284. Hayden, D. M., Forsyth, C. & Keshavarzian, A. The role of matrix metalloproteinases in intestinal epithelial wound healing during normal and inflammatory states. J. Surg. Res. 168, 315-324 (2011).
285. Tugwood, J. D. et al. Fibrodysplasia induced in dog skin by a matrix metalloproteinase (MMP) inhibitor-a mechanistic analysis. Toxicol. Sci. 127, 236-245 (2012).
286. Moake, J. L. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Seminars Hematol. 41, 4-14 (2004).
287. Sela-Passwell, N., Trahtenherts, A., Kruger, A. & Sagi, I. New opportunities in drug design of metalloproteinase inhibitors: combination between structure-function experimental approaches and systems biology. Expert Opin. Drug Discov. 6, 527-542 (2011).
288. Devel, L. et al. Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S1? cavity. Biochimie 92, 1501-1508 (2010).
289. Kothapalli, R. et al. Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain. PLoS ONE 5, e12494 (2010).
290. Hu, J. et al. Inhibition of lethal endotoxin shock with an l-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Comb. Chem. High Throughput Screen. 9, 599-611 (2006).
291. Mannello, F. & Medda, V. Nuclear localization of matrix metalloproteinases. Progress Histochem. Cytochem. 47, 27-58 (2012).
292. Cauwe, B. & Opdenakker, G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 45, 351-423 (2010).
293. Soslau, G. et al. Intracellular matrix metalloproteinase-2 (MMP-2) regulates human platelet activation via hydrolysis of talin. Thromb. Haemostasis 111, 140-153 (2014).
294. Solli, A. I., Fadnes, B., Winberg, J. O., Uhlin-Hansen, L. & Hadler-Olsen, E. Tissue-and cell-specific co-localization of intracellular gelatinolytic activity and matrix metalloproteinase 2. J. Histochem. Cytochem. 61, 444-461 (2013).
295. Sawicki, G. Intracellular regulation of matrix metalloproteinase-2 activity: new strategies in treatment and protection of heart subjected to oxidative stress. Scientifica 2013, 130451 (2013).
296. Zuo, X., Pan, W., Feng, T., Shi, X. & Dai, J. Matrix metalloproteinase 3 promotes cellular anti-dengue virus response via interaction with transcription factor NFκB in cell nucleus. PLoS ONE 9, e84748 (2014).
297. Marchant, D. J. et al. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nature Med. 20, 493-502 (2014).
298. Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775-797 (2013).
299. Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92 (1999).
300. Zhou, Z. et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl Acad. Sci. USA 97, 4052-4057 (2000).
301. Kim, J. W. et al. MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J. Med. Genet. 42, 271-275 (2005).
302. Papagerakis, P. et al. Premature stop codon in MMP20 causing amelogenesis imperfecta. J. Dental Res. 87, 56-59 (2008).
303. Iwasaki, M. et al. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol. Oncol. 85, 103-107 (2002).